scholarly journals Impact of Lifestyle Modifications and Paleo Diet on Selected Obese Subjects

Author(s):  
P. Indumathy ◽  
J. Ramya
2021 ◽  
Vol 9 (B) ◽  
pp. 541-546
Author(s):  
Mohamed Sayed ◽  
Ebthal Mahmoud Abozeid ◽  
Hoda M. Amin ◽  
Naglaa M. Elsayed ◽  
Yasser H. Nassar ◽  
...  

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is currently one of the most prevalent liver diseases. NAFLD is exemplified by the deposition of fat in the liver, in the absence of other etiologies. The spectrum of histological features in NAFLD ranges from macro-vesicular steatosis and nonalcoholic steatohepatitis, and it can eventually end in fibrosis, cirrhosis, or hepatocellular carcinoma. Vitamin D deficiency (VDD) is the most common micronutrient deficiency worldwide. Obese subjects are more prone to VDD, particularly those with liver disease. Non-classic functions of Vitamin D may be involved in the metabolic pathways beyond NAFLD development and progression. AIM: The aim of the study was to evaluate the relationship between NAFLD and Vitamin D levels in extreme obese subjects, and the correlation between Vitamin D levels and NAFLD severity. MATERIALS AND METHODS: The study included 80 Egyptian subjects of both sexes, divided into two groups: 50 patients with Stage III obesity (defined as body mass index [BMI] ≥40 kg/m2) and NAFLD, their age ranging from 20 to <60 years, and 30 age- and sex-matched healthy volunteers as control subjects. All patients were recruited from nutrition outpatient clinic at endocrinology unit, Cairo University Hospitals during the period from January 2019 to June 2019. Diagnosis of NAFLD was done by ultrasonography and laboratory evaluation included Vitamin D level. Nutritional evaluation included BMI, waist circumference, and weight. RESULTS: Vitamin D was significantly lower in the NAFLD group versus healthy controls: About 34%, deficient, 32% insufficient, and 34% sufficient in NAFLD group versus 23.3% insufficient, and 76.7% sufficient only in control, p ˂ 0.001. The severity of NAFLD, as graded by ultrasonography, was positively correlated with BMI and inversely correlated with Vit D levels, p = 0.001 and 0.024, respectively. Multivariate linear regression proved that both BMI and Vit D were independent predictors for NAFLD progression, BMI in a positive manner and Vit D in a negative manner. A cutoff Vit D level of 27.75 had 64% sensitivity and 90% specificity in NAFLD detection, area under the curve was 0.821. CONCLUSION: Vitamin D is significantly lower in the NAFLD group versus healthy controls in this cohort. VDD and BMI were associated with increased NAFLD severity. VDD was found to be an independent predictor of NAFLD progression. Vitamin D supplementation may be added to lifestyle modifications to prevent NAFLD occurrence in obese subjects.


2018 ◽  
Vol 20 (4) ◽  
pp. 422-428 ◽  
Author(s):  
Elizabeth W. Moxley ◽  
Donald Smith ◽  
Lauretta Quinn ◽  
Chang Park

Introduction: Diabetes is a serious health problem affecting approximately 29.1 million individuals in the United States. Another 86 million have prediabetes. The development and implementation of lifestyle modifications such as physical activity for these persons are among the most effective methods for prevention and treatment. Objective: The aim of this study was to examine relationships between glycemic control (HbA1c) and cardiovascular fitness (peak maximal oxygen uptake [VO2 peak] and ventilatory threshold [VT]) in overweight/obese subjects with and without type 2 diabetes (T2DM). In addition, the influences of body mass index (BMI) and insulin sensitivity (homeostasis model assessment [HOMA %S]) on the relationship between glycemic control and cardiovascular fitness were explored. Method: Data were abstracted from a completed study that included 51 overweight or obese subjects with T2DM ( n = 18), impaired glucose tolerance ( n = 8), or normal glucose tolerance ( n = 25). Relationships between glycemic control (HbA1c) and cardiovascular fitness (VO2 peak and VT) were determined using correlational analysis and multiple linear regression analyses. Results: A statistically significant relationship was observed between HbA1c and cardiovascular fitness. However, BMI and HOMA %S did not influence the relationship between glycemic control and cardiovascular fitness. Discussion: HbA1c contributes to VO2 peak and VT in obese and overweight subjects across glucose tolerance categories. Significant results were achieved despite the fact that there was a limited range of HbA1c based on the study inclusion criteria. This finding suggests that even a mild decrease in glycemic control can negatively influence cardiovascular fitness.


Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Alok K Gupta ◽  
Timothy Church ◽  
Wesley W Day

Background: Obesity is associated with increased risk of hypertension (HTN). Weight loss can reduce blood pressure (BP) and prevent progression to HTN. In the CONQUER trial, overweight/obese subjects with ≥2 weight-related comorbidities had significant weight loss over 56 weeks with phentermine plus topiramate extended-release (PHEN/TPM ER) vs placebo when used in combination with a program of lifestyle modifications. Methods: This post hoc analysis of CONQUER evaluated the effects of PHEN/TPM ER on weight, BP, and HTN status over 56 weeks (intent-to-treat population with last observation carried forward). Overweight/obese subjects with normotension (systolic BP/diastolic BP<120/80 mm Hg; 8.7%; n=212), preHTN (120-139/80-89 mm Hg; 19.0%; n=465: both without antiHTN medication use), and HTN (≥140/90 or antiHTN medication use; 72.3%; n=1770) were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92). Results: At week 56, PHEN/TPM ER-treated subjects in all categories (normotension, preHTN, HTN) achieved significant weight loss vs placebo (percentage and absolute; all P <.0001). Systolic BP was improved vs placebo in all categories in subjects receiving PHEN/TPM ER (significant vs placebo in 15/92 group; Table). Fewer subjects with normotension at baseline receiving PHEN/TPM ER progressed to preHTN, and fewer with preHTN at baseline progressed to HTN, vs placebo (Table). A greater percentage of PHEN/TPM ER-treated subjects with preHTN and HTN achieved normotension vs placebo. Most common adverse events in subjects with preHTN and HTN were constipation, dry mouth, and paraesthesia, and in those with normotension were upper respiratory tract infection, dry mouth, and paraesthesia. Conclusion: Overweight/obese subjects treated with PHEN/TPM ER plus lifestyle intervention lost more body weight vs placebo over 56 weeks. This weight loss occurred along with improvements in BP in subjects with normotension, preHTN, and HTN, potentially improving cardiovascular risk.


2016 ◽  
Vol 22 ◽  
pp. 159
Author(s):  
Carolina Casellini ◽  
Joshua Edwards ◽  
Henri Parson ◽  
Kim Hodges ◽  
David Lieb ◽  
...  

2006 ◽  
Author(s):  
Gian Mauro Manzoni ◽  
Gian Luca Cesa ◽  
Daniela Villani ◽  
Gianluca Castelnuovo Enrico Molinari ◽  
Giuseppe Riva

Obesity ◽  
2009 ◽  
Author(s):  
Grant D. Brinkworth ◽  
Manny Noakes ◽  
Peter M. Clifton ◽  
Jonathan D. Buckley

Sign in / Sign up

Export Citation Format

Share Document